On Friday, Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s shares declined -2.93% to $16.59.
Supernus Pharmaceuticals Inc (SUPN) a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, issues the following correction regarding the number of common shares distributed by New Enterprise Associates (NEA). Effective following the close of trading on June 15, 2015, NEA distributed an aggregate of 3,000,000 shares of Supernus Pharmaceuticals common stock to its partners, not 3,921,000 shares as stated earlier. The NEA funds continue to hold about 71% of their original holdings, or 7,647,113 shares, and remain the largest stockholder of Supernus.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products comprise Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy.
Guess?, Inc. (NYSE:GES)’s shares gained 0.96% to $19.88.
Guess?, Inc. (GES) stated financial results for its first quarter ended May 2, 2015.
First Quarter Fiscal 2016 Results
For the first quarter of fiscal 2016, the Company recorded net earnings of $3.3 million, contrast to a net loss of $2.1 million for the first quarter of fiscal 2015. Diluted earnings per share was $0.04, contrast to diluted loss per share of $0.03 for the prior-year quarter, an enhance of $0.07 per share.
Total net revenue for the first quarter of fiscal 2016 reduced 8.4% to $478.8 million, from $522.5 million in the prior-year quarter. In constant currency, total net revenue was roughly flat contrast to the same prior-year period. Refer to the accompanying tables for a summary of the impact of foreign currency exchange rate fluctuations on the Company’s net revenue.
- The Company’s retail stores and e-commerce sites in North America generated revenue of $214.2 million in the first quarter of fiscal 2016, a 6.2% decrease from $228.3 million in the same period a year ago. Comparable store sales counting the results of our e-commerce sites for the first quarter of fiscal 2016 reduced 5.9% in U.S. dollars and 3.8% in constant currency contrast to the same period a year ago.
- Net revenue from the Company’s Europe segment reduced 13.7% to $137.4 million in the first quarter of fiscal 2016, from $159.2 million in the prior-year period. In constant currency, net revenue raised 7.5%.
- Net revenue from the Company’s Asia segment reduced 8.7% to $64.0 million in the first quarter of fiscal 2016, from $70.1 million in the prior-year period. In constant currency, net revenue reduced 6.0%.
Guess?, Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities.
At the end of Friday’s trade, Amazon.com, Inc. (NASDAQ:AMZN)‘s shares decreased -1.02% to $434.92.
Amazon.com, Inc. (AMZN) declared all six episodes of season one of the Amazon Original Series Catastrophe are now accessible exclusively for Amazon Prime members in the US. Written by comedian and best-selling author Rob Delaney (Key & Peele) and award-winning actress Sharon Horgan (Pulling), Catastrophe is a half-hour comedy set in London about an Irish woman and American man struggling to start a relationship after their clumsy lust leads to pregnancy. Already a critical hit in the UK, Catastrophe is an Avalon Television production with co-producers Birdbath Productions and Merman, and is Executive Produced by Richard Allen-Turner (Workaholics), Kara Baker (Iliza Shlezinger: Freezing Hot), Delaney, Horgan, and Jon Thoday (Last Week Tonight with John Oliver). The series is now accessible exclusively for Prime members in the US and will come to Amazon Prime in the UK later this year.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates in two segments, North America and International. The company serves consumers through retail Websites, such as amazon.com and amazon.ca, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
Lion Biotechnologies Inc (NASDAQ:LBIO), ended its Friday’s trading session with -1.01% loss, and closed at $9.76.
Lion Biotechnologies Inc (LBIO) declared that the FDA has granted orphan status to the company’s lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma.
The FDA grants orphan status to novel drugs or biologics to treat rare medical diseases or conditions that affect fewer than 200,000 people in the United States. By receiving this designation for LN-144, Lion will be eligible for tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product comprises LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
